drugset / Trial / NCT00336648
Preop Chemoradiation Resectable Pancreas
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary Objective: 1\. To assess resectability rate in patients undergoing gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreas. Secondary Objectives: 1. To assess disease free survival and overall survival 2. To assess margin resection rate (R0 vs. R1) in these patients 3. To assess patterns of failure
Timeline
- Start
- 2006-06
- Primary completion
- 2007-09
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 400 mg/m2 | Intravenous |